OClawVPS.com
CDH Investments
Edit

CDH Investments

https://www.cdhfund.com/
Last activity: 25.10.2025
Active
Established in 2002, CDH Investments is one of the leading alternative investment fund managers focused on China today with over US$19 billion of assets under management, as of December 31, 2019. CDH was founded by WU Shangzhi, JIAO Shuge and four other investment professionals who worked together in the direct investment department of China International Capital Corporation beginning in 1995. From its roots in private equity, CDH has expanded to become a diversified alternative asset management platform covering: Private Equity, Real Assets, Venture and Growth Capital, Mezzanine&Credit, Public Equities and Wealth Management. CDH has more than 100 investment professionals working in offices in Hong Kong, Singapore, Beijing, Shanghai and Shenzhen. CDH has invested in more than 180 companies and has helped more than 50 companies successfully list on international and China’s domestic stock exchanges. As of 2016, these companies employ more than 500,000 people. Many of them are sector leaders, and, collectively, they play an important role in China’s economy. CDH’s core principle is to create value for all of our partners, including investors and portfolio companies. We continually strive to embody this principle and make it the basis for all of our decisions. We maintain close cooperative partnerships with over 100 international and local institutional investors.
Followers
17.46K
Portfolio
2
Mentions
21
Employees: 201-500
Founded date: 2002
Investment Stage: Series D

Portfolio 2

DateNameWebsiteTotal RaisedLocation
24.10.2025Neolixneolix.cn$629MChina
23.09.2025AusperBioausperbio.com$186M-

Mentions in press and media 21

DateTitleDescription
25.10.2025Neolix: Over $600 Million Series D Funding Raised To Advance China’s Autonomous Driving IndustryNeolix, the world’s largest provider of Level 4 (L4) autonomous delivery vehicles, has completed a record-breaking $600 million Series D funding round, the most significant private financing in the history of China’s autonomous driving sect...
24.10.2025Neolix Secures Record $600M Funding, Drives Global Autonomous Delivery FutureNeolix secured over $600M in record Series D funding, dominating China's autonomous delivery sector. This L4 RoboVan leader holds over 60% market share. Its advanced AI, including map-free navigation and vision-action models, redefines logi...
24.10.2025Neolix Raises Over USD$600M in Series D FundingNeolix, a Beijing, China-based provider of L4 autonomous delivery (RoboVan) solutions, raised over US$600m in Series D financing. The round was led by UAE-based Stone Venture, joined by Gaocheng Capital, CITIC Capital, CDH, Sparkedge Capita...
24.10.2025Neolix Raises US$600+ Million in Series D Funding, Setting New Record for Private Financing of China's Autonomous Driving IndustryBEIJING, Oct. 24, 2025 /PRNewswire/ -- Neolix, the world's largest provider of L4 autonomous delivery (RoboVan) solutions, has raised over US$600 million in its Series D financing. By deal size, it is the largest private fundraising in Chin...
24.10.2025Neolix Raises US$600+ Million in Series D, Setting New Record for China's Autonomous Driving IndustryBEIJING, Oct. 24, 2025 /PRNewswire/ -- Neolix, the world's largest provider of L4 autonomous delivery (RoboVan) solutions, has raised over US$600 million in its Series D financing. This round marks the largest private fundraising in China's...
19.10.2025CHANDO Group: Over $40 Million Raised From Harvest Capital And L’Oréal Partnership SignedHarvest Capital has invested ¥300 million (over $40 million) in CHANDO Group, one of China’s leading homegrown beauty companies. Global beauty giant L’Oréal also participated in the round as an industrial partner. The partnership underscore...
26.09.2025AusperBio Secures $63 Million for Targeted Hepatitis B CureAusperBio, a clinical-stage biotechnology firm, closed a $63 million Series B2 funding round. This substantial capital infusion will accelerate its mission. The company develops targeted oligonucleotide therapies. Its lead candidate, AHB-13...
25.09.2025[Corrected] CDH Investments engages buyers for multi-asset CV-
23.09.2025AusperBio: $63 Million Closed For Advancing Targeted Oligonucleotide TherapiesAusperBio, a biotechnology company focused on curing chronic hepatitis B, has announced it raised $63 million in Series B2 funding. This new investment adds to the strong financial backing the company has already received and reflects growi...
22.09.2025AusperBio Raises $63M in Series B2 FundingAusperBio, a San Francisco, CA-based privately held clinical-stage biotechnology company, raised $63M in Series B2 Funding. The round was led by Qiming Venture Partners with participation from HanKang Capital, CDH Investments, YuanBio Ventu...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In